Fady Ibraham Malik Insider Trades & Stock Holdings
Fady Ibraham Malik, EVP Research & Development at Cytokinetics, Incorporated has 1 Form 4 trade on file since Oct 20, 2026. Open-market activity: 0 purchases ($0) and 1 sale ($224.03K), net -$224.03K. Latest filing: disposed of 3.50K shares of $CYTK on Oct 20, 2026 at $64.01.
- Trades on file
- 1
- Open-market bought
- $0
- Open-market sold
- $224.03K
- Net open-market
- -$224.03K
- Shares held ($CYTK)
- 153.90K
- Latest filing
- Oct 20, 2026
Shares held by Fady Ibraham Malik
Shares owned after the most recent Form 4 for each company.
All insider trades by Fady Ibraham Malik
| Date | Ticker | Type | Shares | Price | Value | Owned after | ΔOwn | 1W | 1M | 6M | Role | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $CYTK | Sell (Open-market sale) 10b5-1 | 3.50K | $64.01 | $224.03K | 153.90K | -2.22% | EVP Research & Development | SEC | Read |
"Buy" means shares acquired on the Form 4 (including grants and option exercises); "Sell" means shares disposed. 1W / 1M / 6M = how the stock moved after the trade.
Stocks Fady Ibraham Malik traded
Frequently asked questions
Has Fady Ibraham Malik been buying or selling stock?
Fady Ibraham Malik has 0 open-market purchases and 1 open-market sale on file, net -$224.03K. Grants, option exercises and tax withholding are listed separately because they are not open-market trades.
What was Fady Ibraham Malik's latest insider trade?
disposed of 3.50K shares of $CYTK on Oct 20, 2026 at $64.01.
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Reply STOP anytime.
SMS Terms
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.